Liquid biopsy in colorectal cancer – the time has come?
Recent findings from studies confirm the promises of ctDNA in this setting, but unanswered questions still remain about timing and methodology
Advanced genetic testing is largely inaccessible to cancer patients across Europe
An ESMO study shows that precision oncology is out of reach for the majority of patients, with costs of technologies and reimbursement policies acting as major barriers
Cancer Research
On the horizon of translational research
Tumour agnostic targeted agents and ‘smarter’ dynamic designs are two major areas of interest leading to more patient-centric approaches in cancer care
“Green” prescribing may limit the environmental impact of oncology
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices
When your patient is the global population
Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team
Early-phase data from targeting HER3 with ADC are encouraging
Some studies presented suggest preliminary activity of patritumab–deruxtecan in patients with HR-positive/HER2-negative disease and triple-negative breast cancer
Extended safety information and PROs data support key trial results in metastatic breast cancer
Data presentations from DESTINY-Breast04, DESTINY-Breast02 and EMERALD trials confirm the value of trastuzumab deruxtecan and elacestrant in this setting, despite moderate drop-out rates for PROs
Does AI hold the future of early cancer detection?
Technology promises to improve understanding of cancer risk and lesion biology, but clear regulation is urged to implement innovation in cancer screening programmes
Challenging past dogma in breast cancer research – what's next?
In her keynote lecture, recipient of the ESMO Breast Cancer Award 2023, Prof. Sara A. Hurvitz talks of the need to challenge accepted paradigms to progress clinical research
Breast cancer leads the way in ADC therapy
Lessons learned from the use of second-generation antibody–drug conjugates (ADCs) in breast cancer can direct treatment in other tumour types